Page 3 - Fosun Pharmaceutical

Prices of oral diabetes drugs set to fall as patents near expiry date

The diabetes segment has been growing faster than the country's overall drug market

Fosun Pharma acquires 74% stake in Gland Pharma for $1.09 bn

Fosun Pharma and Fosun International said following the completion of the acquisition, Gland Pharma has become an indirect non-wholly owned subsidiary of Fosun Pharma and Fosun International

China's Fosun to buy 74% stake in Gland Pharma for $1.1 bn in revised deal

India allows foreign investment of up to 100% in pharmaceutical sector but above 74% requires govt approval

Fosun Pharma to buy 74% stake in Gland for $1.09 billion

Agrees to cut size of stake in Hyderabad-based injectable maker to 74%, after earlier proposal to acquire 86% met approval roadblock

China's Fosun Pharma to buy smaller stake in Gland Pharma for $1.09 bn

Revised plan in wake of Indian firm's demand to retain higher stake

China's Fosun, Shanghai Pharma bid for stake in US-based drugmaker Arbor

Shanghai Pharma also said it had submitted a non-binding bid for a stake in Arbor already

Shanghai Fosun seals Gland Pharma deal

Chinese firm buys Hyderabad-based injectables maker at $1.46 bn valuation; promoter family retains 10%; KKR exit earns it threefold return in 30 months

China's Fosun to buy Gland Pharma for $1.26 billion

Will acquire 86% stake in KKR-backed Indian firm, signs definitive agreement for the largest acquisition of an Indian company by a Chinese firm

Fosun to buy KKR-backed Indian drugmaker for up to $1.3 bn

The largest inbound acquisition of an Indian company from abroad this year

Shanghai Fosun Pharma halts share trading

Trading halt assumes significance in the backdrop of Fosun's bid to acquire Gland Pharma

China's Fosun to sign agreement for $1.4 billion Gland Pharma buy: Report

In May, Shanghai Fosun had made a non-binding proposal to buy Gland Pharma